SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 8, nr. 4, 2013

ISSN 1841-9038  |  e-ISSN 2069-6116
ISSN-L 1841-9038
CNCSIS - CMR - B+

HIGHLIGHTS

Plagiatul – in actualitate

Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

Committe on Publication Ethics

A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

Members Area


Teriflunomide – A New Oral Agent for Multiple Sclerosis Treatment

Teriflunomide is an oral immunomodu lator, an active metabolite of leflunomide. Leflunomide is used in the long-term treatment of rheumatoid arthritis and is metabolized to te riflunomide in vivo.

The mechanism of action of teriflunomide is linked to reversibly inhibition of dihydroorotate dehydrogenase, a mithocondrial enzyme involved in de novo synthesis of pyrimidine for DNA replication. The consequence of this mechanism of action is the blockade of activation and proliferation of stimulated lymphocytes (T and B cells).

Full text | PDF